Epidermal Growth Factor (EGF) receptor overexpression, KRAS, TP53, CDKN2A and SMAD4 mutations characterize pancreatic ductal adenocarcinoma. Here, CDKN2A is linked to pancreatic ductal adenocarcinoma.